Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...
Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...
Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...
Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data readout ...
MedPage Today on MSN16h
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisA novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...
Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback